ZA201905212B - Rescue treatment of post operative nausea and vomiting - Google Patents
Rescue treatment of post operative nausea and vomitingInfo
- Publication number
- ZA201905212B ZA201905212B ZA2019/05212A ZA201905212A ZA201905212B ZA 201905212 B ZA201905212 B ZA 201905212B ZA 2019/05212 A ZA2019/05212 A ZA 2019/05212A ZA 201905212 A ZA201905212 A ZA 201905212A ZA 201905212 B ZA201905212 B ZA 201905212B
- Authority
- ZA
- South Africa
- Prior art keywords
- vomiting
- post operative
- rescue treatment
- operative nausea
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1702250.0A GB201702250D0 (en) | 2017-02-10 | 2017-02-10 | Method |
| PCT/GB2018/050374 WO2018146490A1 (en) | 2017-02-10 | 2018-02-09 | Rescue treatment of post operative nausea and vomiting |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201905212B true ZA201905212B (en) | 2023-12-20 |
Family
ID=58462198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2019/05212A ZA201905212B (en) | 2017-02-10 | 2019-08-07 | Rescue treatment of post operative nausea and vomiting |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11357753B2 (enExample) |
| EP (1) | EP3579831A1 (enExample) |
| JP (2) | JP7333269B2 (enExample) |
| KR (2) | KR20190111993A (enExample) |
| CN (1) | CN110603036A (enExample) |
| AU (2) | AU2018218310B2 (enExample) |
| BR (1) | BR112019016565A2 (enExample) |
| CA (1) | CA3052535A1 (enExample) |
| EA (1) | EA201991667A1 (enExample) |
| GB (1) | GB201702250D0 (enExample) |
| IL (2) | IL298486B2 (enExample) |
| MX (1) | MX388736B (enExample) |
| WO (1) | WO2018146490A1 (enExample) |
| ZA (1) | ZA201905212B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201702250D0 (en) * | 2017-02-10 | 2017-03-29 | Acacia Pharma Ltd | Method |
| IT201900013524A1 (it) * | 2019-07-31 | 2021-01-31 | Laboratori Baldacci Spa | Nuove formulazioni di amisulpride |
| WO2022008901A1 (en) * | 2020-07-06 | 2022-01-13 | Acacia Pharma Ltd | Therapy of post-operative nausea and vomiting |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1004020A (en) | 1964-04-24 | 1965-09-08 | Standard Telephones Cables Ltd | Improvements in or relating to the mounting of electrical components |
| FR2415099A1 (fr) | 1978-01-20 | 1979-08-17 | Ile De France | Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes |
| GB9305593D0 (en) | 1993-03-18 | 1993-05-05 | Smithkline Beecham Plc | Pharmaceuticals |
| US6169094B1 (en) | 1998-07-14 | 2001-01-02 | Sanofi-Synthelabo | Compositions of (S) (-)-amisulpride |
| DE10163421A1 (de) | 2001-12-21 | 2003-07-31 | Gruenenthal Gmbh | Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum |
| MY143789A (en) | 2003-02-18 | 2011-07-15 | Helsinn Healthcare Sa | Use of palonosetron treating post- operative nausea and vomiting |
| DE102005013726A1 (de) | 2005-03-22 | 2006-09-28 | Grünenthal GmbH | Transdermale therapeutische Systeme mit verbesserter Verträglichkeit |
| GB0506800D0 (en) | 2005-04-04 | 2005-05-11 | Merck Sharp & Dohme | New uses |
| WO2007067714A2 (en) | 2005-12-08 | 2007-06-14 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| AU2007211091B8 (en) | 2006-01-27 | 2013-08-29 | Adare Pharmaceuticals, Inc. | Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids |
| EP1988883A1 (fr) | 2006-02-17 | 2008-11-12 | Trimaran Limited | Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions |
| US7825156B2 (en) | 2007-02-02 | 2010-11-02 | Copharms | Method of treating bipolar depression with a benzamide derivative |
| EP2240022B1 (en) | 2008-01-09 | 2016-12-28 | Charleston Laboratories, Inc. | Bilayered tablets comprising oxycodone and promethazine |
| US8138169B2 (en) | 2008-04-11 | 2012-03-20 | Comgenrx, Inc. | Combination therapy for bipolar disorder |
| US20110003005A1 (en) | 2009-07-06 | 2011-01-06 | Gopi Venkatesh | Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions |
| RS53491B1 (sr) | 2009-11-18 | 2015-02-27 | Helsinn Healthcare Sa | Kompozicije za lečenje centralno posredovane mučnine i povraćanja |
| GB201004020D0 (en) | 2010-03-11 | 2010-04-21 | Acacia Pharma Ltd | New therapeutic use |
| MX353209B (es) | 2010-06-18 | 2018-01-08 | Altos Therapeutics Llc | Antagonistas d2, metodos de sintesis y metodos de uso. |
| WO2015054429A1 (en) | 2013-10-08 | 2015-04-16 | Innopharma, Inc | Aprepitant oral liquid formulations |
| GB201506116D0 (en) * | 2015-04-10 | 2015-05-27 | Acacia Pharma Ltd | Kit and combination therapy for nausea and vomiting |
| GB201618425D0 (en) | 2016-11-01 | 2016-12-14 | Acacia Pharma Ltd | method |
| GB201702250D0 (en) * | 2017-02-10 | 2017-03-29 | Acacia Pharma Ltd | Method |
-
2017
- 2017-02-10 GB GBGB1702250.0A patent/GB201702250D0/en not_active Ceased
-
2018
- 2018-02-09 MX MX2019009507A patent/MX388736B/es unknown
- 2018-02-09 CA CA3052535A patent/CA3052535A1/en active Pending
- 2018-02-09 IL IL298486A patent/IL298486B2/en unknown
- 2018-02-09 KR KR1020197023506A patent/KR20190111993A/ko not_active Ceased
- 2018-02-09 AU AU2018218310A patent/AU2018218310B2/en active Active
- 2018-02-09 EA EA201991667A patent/EA201991667A1/ru unknown
- 2018-02-09 BR BR112019016565-7A patent/BR112019016565A2/pt not_active Application Discontinuation
- 2018-02-09 WO PCT/GB2018/050374 patent/WO2018146490A1/en not_active Ceased
- 2018-02-09 US US16/485,008 patent/US11357753B2/en active Active
- 2018-02-09 IL IL268591A patent/IL268591B2/en unknown
- 2018-02-09 EP EP18705483.8A patent/EP3579831A1/en active Pending
- 2018-02-09 JP JP2019543311A patent/JP7333269B2/ja active Active
- 2018-02-09 KR KR1020237044292A patent/KR20240001288A/ko active Pending
- 2018-02-09 CN CN201880011444.1A patent/CN110603036A/zh active Pending
-
2019
- 2019-08-07 ZA ZA2019/05212A patent/ZA201905212B/en unknown
-
2022
- 2022-05-17 US US17/746,032 patent/US12005042B2/en active Active
- 2022-12-08 JP JP2022196161A patent/JP7526244B2/ja active Active
-
2024
- 2024-05-02 US US18/653,318 patent/US12329740B2/en active Active
- 2024-05-13 AU AU2024203155A patent/AU2024203155B2/en active Active
-
2025
- 2025-05-19 US US19/211,545 patent/US20250367211A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200038369A1 (en) | 2020-02-06 |
| US20250367211A1 (en) | 2025-12-04 |
| EA201991667A1 (ru) | 2020-02-11 |
| US20240285579A1 (en) | 2024-08-29 |
| IL268591B (en) | 2022-12-01 |
| IL298486A (en) | 2023-01-01 |
| MX388736B (es) | 2025-03-20 |
| US20230100786A1 (en) | 2023-03-30 |
| JP2020506209A (ja) | 2020-02-27 |
| AU2024203155B2 (en) | 2025-03-13 |
| CN110603036A (zh) | 2019-12-20 |
| IL268591B2 (en) | 2023-04-01 |
| IL298486B1 (en) | 2024-05-01 |
| IL298486B2 (en) | 2024-09-01 |
| AU2018218310A1 (en) | 2019-08-22 |
| NZ756051A (en) | 2024-04-26 |
| US11357753B2 (en) | 2022-06-14 |
| CA3052535A1 (en) | 2018-08-16 |
| US12005042B2 (en) | 2024-06-11 |
| AU2018218310B2 (en) | 2024-02-15 |
| KR20190111993A (ko) | 2019-10-02 |
| EP3579831A1 (en) | 2019-12-18 |
| KR20240001288A (ko) | 2024-01-03 |
| WO2018146490A1 (en) | 2018-08-16 |
| BR112019016565A2 (pt) | 2020-03-31 |
| JP2023027213A (ja) | 2023-03-01 |
| AU2024203155A1 (en) | 2024-05-30 |
| IL268591A (en) | 2019-09-26 |
| JP7526244B2 (ja) | 2024-07-31 |
| GB201702250D0 (en) | 2017-03-29 |
| US12329740B2 (en) | 2025-06-17 |
| JP7333269B2 (ja) | 2023-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201290833A1 (ru) | Применение амисульприда в качестве противорвотного средства | |
| MX2021002321A (es) | Nuevos metodos. | |
| IL268960A (en) | 7,6,5,4-Tetrahydroisoxazazole (4,5-c) Pyridin-3-ol (thip) for use in the treatment of broken x syndrome | |
| MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| EP4272818A3 (en) | Thrombolytic agent for the treatment of thromboembolism | |
| EP4512394A3 (en) | Dosage forms and use thereof | |
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| WO2018165404A8 (en) | Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol | |
| ZA202006072B (en) | Ret inhibitor for use in treating cancer having a ret alteration | |
| ZA201905212B (en) | Rescue treatment of post operative nausea and vomiting | |
| AU2018282104A1 (en) | Use of vibegron to treat overactive bladder | |
| MX2016014699A (es) | (s)-pirlindol o sus sales farmaceuticamente aceptables para uso en medicina. | |
| NZ751972A (en) | Treatment of prurigo nodularis | |
| MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
| WO2020243273A3 (en) | Methods of treating cholangiocarcinoma | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| AR102308A1 (es) | Composición farmacéutica para usar en el tratamiento o prevención de deficiencias de vitaminas y minerales en pacientes sometidos a cirugía de bypass gástrico | |
| MX2018005876A (es) | Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas. | |
| PH12020500606A1 (en) | Use of functionalized calcium carbonate as active ingredient | |
| UA117833U (uk) | Спосіб лікування синдрому післяопераційної нудоти та блювання у пацієнтів після лапароскопічної холецистектомії | |
| NZ760052A (en) | Methods of treatment for cystic fibrosis | |
| MDS20160124U2 (ro) | Metodă de profilaxie a limforeii prolongate în tratamentul radical al cancerului glandei mamare la pacientele cu diabet zaharat tip 2 | |
| MX2021004997A (es) | Tratamiento y prevencion de la eyaculacion precoz (ep). |